Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Nov 5:15:1490853.
doi: 10.3389/fphar.2024.1490853. eCollection 2024.

Editorial: Towards continued and affordable accessibility of innovative drugs: sustainable development and efficient use of medicines

Atse H Huisman  1   2 , Denise van den Berg  3 , Saco de Visser  4 , Bettina Ryll  5   6 , Sahar Barjesteh van Waalwijk van Doorn-Khosrovani  1   7
Affiliations
Editorial

Editorial: Towards continued and affordable accessibility of innovative drugs: sustainable development and efficient use of medicines

Atse H Huisman et al. Front Pharmacol. .
No abstract available

Keywords: access; affordability and accessibility of medicines; compounding; cost-efectiveness; de-escalation; expensive drugs; precision medicine; repurposing.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Towards continued and affordable accessibility of innovative drugs: sustainable development and efficient use of medicines

References

    1. Barjesteh van Waalwijk van Doorn-Khosrovani S., van der Flier S., van den Berg D. (2022). Novel ways to fund cost-efficiency studies of expensive drugs: efforts to maintain sustainable healthcare expenditure in the Netherlands. J. Clin. Oncol. 40, e18831. 10.1200/jco.2022.40.16_suppl.e18831 - DOI
    1. de Visser S. J., van den Berg S., Mosterd A., Lo D. C. (2024). Reliable business case for repurposing of existing medicines requires key changes in government policies. Drug Discov. Today 29, 104096. 10.1016/j.drudis.2024.104096 - DOI - PubMed
    1. Rohaan M. W., Borch T. H., van den Berg J. H., Met Ö., Kessels R., Geukes Foppen M. H., et al. (2022). Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 387, 2113–2125. 10.1056/NEJMoa2210233 - DOI - PubMed
    1. Saesen R., Espinasse C., Pignatti F., Lacombe D. (2022). Advancing academia-driven treatment optimisation in oncology: launch of the EMA cancer medicines Forum. Eur. J. Cancer 168, 77–79. 10.1016/j.ejca.2022.03.025 - DOI - PubMed
    1. Smale E. M., van den Bemt B. J. F., Heerdink E. R., Desar I. M. E., Egberts T. C. G., Bekker C. L., et al. (2023). Cost savings and waste reduction through redispensing unused oral anticancer drugs: the ROAD study. JAMA Oncol. 10, 87–94. 10.1001/jamaoncol.2023.4865 - DOI - PMC - PubMed

Publication types

LinkOut - more resources